Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) has undergone a significant leadership transition, with Doug Drysdale stepping down as Chief Executive Officer effective September 2, 2025. Co-Founder and President Eric So has assumed the role of interim CEO while the Board of Directors conducts a search for a permanent successor to lead the company through its commercialization phase.
The leadership change comes at a critical juncture for Cybin, a late-stage neuropsychiatry company developing next-generation psychedelic-based treatments for mental health conditions. The company's clinical pipeline includes CYB003, a proprietary deuterated psilocin analog currently in Phase 3 studies for adjunctive treatment of major depressive disorder. This treatment has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, indicating its potential to address significant unmet medical needs.
Additionally, Cybin is advancing CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in Phase 2 studies for generalized anxiety disorder. The company maintains a research pipeline of investigational compounds focused on 5-HT receptors, positioning itself at the forefront of psychedelic medicine development. Investors can access the latest news and updates relating to CYBN through the company's newsroom at https://ibn.fm/CYBN.
The interim leadership structure allows Eric So to focus on advancing Cybin's clinical pipeline while ensuring continuity during this transitional period. This strategic move separates the commercialization leadership needs from the clinical development focus, potentially optimizing both aspects of the business. The formation of a dedicated CEO search committee underscores the board's commitment to finding leadership capable of navigating the complex regulatory and market landscape of psychedelic medicines.
This leadership transition signals Cybin's progression from research and development toward commercialization readiness. The timing coincides with the company's advanced clinical trials, suggesting preparation for potential market entry of its psychedelic-based therapies. The mental health treatment landscape stands to benefit from Cybin's innovative approach, particularly given the large unmet need for effective and durable treatment options that the company aims to address through its novel drug development programs.
The full details of this executive transition are available in the official press release at https://ibn.fm/dZEte. This development represents a pivotal moment for Cybin as it positions itself to potentially revolutionize mental healthcare through scientifically validated psychedelic treatments, while navigating the complex regulatory environment surrounding psychedelic medicines.
